Simon F Lacey

List of Publications by Citations

64 papers	14,316 citations	37 h-index	71 g-index
71 ext. papers	18,644 ext. citations	15.8 avg, IF	5.94 L-index

#	Paper	IF	Citations
64	Chimeric antigen receptor T cells for sustained remissions in leukemia. *New England Journal of Medicine*, **2014**, 371, 1507-17	59.2	3305
63	Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. *Science Translational Medicine*, **2015**, 7, 303ra139	17.5	1071
62	Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. *New England Journal of Medicine*, **2017**, 377, 2545-2554	59.2	951
61	Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. *Science*, **2020**, 369,	33.3	744
60	Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. *Cancer Discovery*, **2015**, 5, 1282-95	24.4	713
59	A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. *Science Translational Medicine*, **2017**, 9,	17.5	697
58	Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. *Nature Medicine*, **2018**, 24, 563-571	50.5	649
57	Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. *Cancer Discovery*, **2016**, 6, 664-79	24.4	603
56	NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. *Nature Medicine*, **2015**, 21, 914-921	50.5	543
55	CRISPR-engineered T cells in patients with refractory cancer. *Science*, **2020**, 367,	33.3	448
54	Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. *New England Journal of Medicine*, **2015**, 373, 1040-7	59.2	417
53	Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. *Nature*, **2018**, 558, 307-312	50.4	362
52	B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. *Journal of Clinical Investigation*, **2019**, 129, 2210-2221	15.9	312
51	Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. *Nature Medicine*, **2018**, 24, 1499-1503	50.5	286
50	PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. *Blood*, **2017**, 129, 1039-1041	2.2	285
49	Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. *Blood*, **2016**, 127, 1117-27	2.2	282
48	Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. *JCI Insight*, **2018**, 3,	9.9	250

47	Dominant-Negative TGF-Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. *Molecular Therapy*, **2018**, 26, 1855-1866	11.7	247
46	Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. *Gastroenterology*, **2018**, 155, 29-32	13.3	209
45	Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer. *Cancer Immunology Research*, **2017**, 5, 1152-1161	12.5	181
44	Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. *Blood*, **2017**, 130, 2317-2325	2.2	180
43	Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. *Blood*, **2016**, 128, 360-70	2.2	143
42	The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. *Clinical Cancer Research*, **2016**, 22, 2684-96	12.9	108
41	Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. *Journal of Immunological Methods*, **2016**, 434, 1-8	2.5	108
40	Reducing Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells. *Cancer Immunology Research*, **2018**, 6, 1100-1109	12.5	105
39	Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. *Molecular Therapy*, **2019**, 27, 1919-1929	11.7	101
38	Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. *JCI Insight*, **2018**, 3,	9.9	90
37	Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. *Journal of Clinical Oncology*, **2020**, 38, 415-422	2.2	80
36	Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL.. *Journal of Clinical Oncology*, **2016**, 34, 3011-3011	2.2	74
35	Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. *PLoS Pathogens*, **2017**, 13, e1006613	7.6	68
34	Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients. *Molecular Therapy*, **2018**, 26, 269-279	11.7	63
33	Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma. *OncoImmunology*, **2018**, 7, e1468956	7.2	60
32	Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventions **2020**,		52
31	Neurotoxicity after CTL019 in a pediatric and young adult cohort. *Annals of Neurology*, **2018**, 84, 537-546	9.4	49
30	CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. *Journal of Clinical Investigation*, **2020**, 130, 673-685	15.9	45

29	Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. *Journal of Clinical Oncology*, **2020**, 38, 2862-2871	2.2	45
28	CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success. *Frontiers in Immunology*, **2018**, 9, 2740	8.4	45
27	Decade-long leukaemia remissions with persistence of CD4 CAR T cells.. *Nature*, **2022**,	50.4	30
26	Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma. *Blood*, **2016**, 128, 974-974	2.2	27
25	Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies. *Blood Advances*, **2019**, 3, 2487-2490	7.8	23
24	Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide. *Blood*, **2016**, 128, 5702-5702	2.2	23
23	Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. *Nature Medicine*, **2021**, 27, 842-850	50.5	22
22	An NK-like CAR T cell transition in CAR T cell dysfunction. *Cell*, **2021**, 184, 6081-6100.e26	56.2	15
21	Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma. *OncoImmunology*, **2020**, 9, 1676615	7.2	15
20	CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. *Journal of Clinical Investigation*, **2021**, 131,	15.9	15
19	Biomarkers of Response to Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Chronic Lymphocytic Leukemia. *Blood*, **2016**, 128, 57-57	2.2	14
18	Pilot study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma.. *Journal of Clinical Oncology*, **2016**, 34, 2067-2067	2.2	14
17	Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma. *Blood*, **2019**, 134, 1863-1863	2.2	13
16	Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. *Molecular Therapy*, **2020**, 28, 2367-2378	11.7	13
15	Systemic Endothelial Activation Is Associated With Early Acute Respiratory Distress Syndrome in Children With Extrapulmonary Sepsis. *Critical Care Medicine*, **2020**, 48, 344-352	1.4	11
14	Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. *Blood Advances*, **2020**, 4, 5174-5183	7.8	10
13	Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. *Blood*, **2021**,	2.2	10
12	IMCT-15PILOT STUDY OF T CELLS REDIRECTED TO EGFRvIII WITH A CHIMERIC ANTIGEN RECEPTOR IN PATIENTS WITH EGFRvIII+ GLIOBLASTOMA. *Neuro-Oncology*, **2015**, 17, v110.4-v111	1	9

11	Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma. *Frontiers in Oncology*, **2021**, 11, 669071	5.3	8
10	Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome. *Blood*, **2020**, 136, 1980-1983	2.2	7
9	First Trial of CRISPR-Edited T cells in Lung Cancer. *Trends in Molecular Medicine*, **2020**, 26, 713-715	11.5	7
8	First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma. *Blood*, **2019**, 134, 49-49	2.2	7
7	Engineered T Cell Therapies from a Drug Development Viewpoint. *Engineering*, **2019**, 5, 140-149	9.7	7
6	Biomarkers in T-cell therapy clinical trials. *Cytotherapy*, **2013**, 15, 632-40	4.8	6
5	BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. *Journal of Clinical Investigation*, **2021**, 131,	15.9	6
4	Stable HLA antibodies following sustained CD19+ cell depletion implicate a long-lived plasma cell source. *Blood Advances*, **2020**, 4, 4292-4295	7.8	5
3	The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. *Clinical Cancer Research*, **2021**, 27, 6580-6590	12.9	1
2	B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy. *British Journal of Haematology*, **2021**, 193, 851-855	4.5	0
1	Autologous CD4 T Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals. *Molecular Therapy*, **2021**, 29, 626-635	11.7	0